These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17547500)

  • 21. The effects of intravaginal clindamycin and metronidazole therapy on vaginal lactobacilli in patients with bacterial vaginosis.
    Nyirjesy P; McIntosh MJ; Gattermeir DJ; Schumacher RJ; Steinmetz JI; Joffrion JL
    Am J Obstet Gynecol; 2006 May; 194(5):1277-82. PubMed ID: 16647910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for the treatment of bacterial vaginosis: focus on tinidazole.
    Dickey LJ; Nailor MD; Sobel JD
    Ther Clin Risk Manag; 2009 Jun; 5(3):485-9. PubMed ID: 19707258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization and Treatment of Recurrent Bacterial Vaginosis.
    Faught BM; Reyes S
    J Womens Health (Larchmt); 2019 Sep; 28(9):1218-1226. PubMed ID: 31403349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacterial vaginosis. An evaluation of treatment.
    Piot P
    Scand J Urol Nephrol Suppl; 1984; 86():229-35. PubMed ID: 6336137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tinidazole in the treatment of bacterial vaginosis.
    Armstrong NR; Wilson JD
    Int J Womens Health; 2010 Aug; 1():59-65. PubMed ID: 21072275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis.
    Gillis JC; Wiseman LR
    Drugs; 1996 Apr; 51(4):621-38. PubMed ID: 8706597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gynalgin--one more opportunity in the treatment of bacterial vaginosis].
    Dimitrova A; Shopova E; Timeva T
    Akush Ginekol (Sofiia); 2007; 46(1):46-7. PubMed ID: 17469464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis.
    Bannatyne RM; Smith AM
    Sex Transm Infect; 1998 Dec; 74(6):455-6. PubMed ID: 10195061
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibacterial activity and pharmacokinetics of nitroimidazoles. A review.
    Bergan T
    Scand J Infect Dis Suppl; 1985; 46():64-71. PubMed ID: 3865352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects.
    Brandt M; Abels C; May T; Lohmann K; Schmidts-Winkler I; Hoyme UB
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):158-62. PubMed ID: 18775597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tinidazole as a prophylactic agent in hysterectomy: a clinical and pharmacokinetic comparison with metronidazole.
    Seligman SA
    Pharmatherapeutica; 1981; 3(1):67-70. PubMed ID: 7323109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy.
    Donders GG; Van Calsteren K; Bellen G; Reybrouck R; Van den Bosch T; Riphagen I; Van Lierde S
    BJOG; 2009 Sep; 116(10):1315-24. PubMed ID: 19538417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review.
    Barrons R; Tassone D
    Clin Ther; 2008 Mar; 30(3):453-68. PubMed ID: 18405785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Part XI. Trimethoprim-sulfamethoxazole, nitrofurantoin, chloramphenicol, metronidazole and tinidazole, rifaximin, and nitazoxanide.
    Sud B; Salvaggio M; Greenfield R; Bronze MS
    J Okla State Med Assoc; 2007 Jul; 100(7):267-72. PubMed ID: 17896614
    [No Abstract]   [Full Text] [Related]  

  • 35. Metronidazole for the treatment of vaginal infections.
    Sobel R; Sobel JD
    Expert Opin Pharmacother; 2015 May; 16(7):1109-15. PubMed ID: 25887246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tinidazole inhibitory and cidal activity against anaerobic periodontal pathogens.
    Alou L; Giménez MJ; Manso F; Sevillano D; Torrico M; González N; Granizo JJ; Bascones A; Prieto J; Maestre JR; Aguilar L
    Int J Antimicrob Agents; 2009 May; 33(5):449-52. PubMed ID: 19097755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.
    Nyirjesy P; Schwebke JR
    Future Microbiol; 2018 Apr; 13():507-524. PubMed ID: 29327947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of bacterial vaginosis: what we have and what we miss.
    Donders GG; Zodzika J; Rezeberga D
    Expert Opin Pharmacother; 2014 Apr; 15(5):645-57. PubMed ID: 24579850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secnidazole (Solosec) for bacterial vaginosis.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):52-53. PubMed ID: 29635264
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of metronidazole-resistant Trichomonas vaginalis--a new approach.
    Mammen-Tobin A; Wilson JD
    Int J STD AIDS; 2005 Jul; 16(7):488-90. PubMed ID: 16004628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.